Knife Capital, a South African venture capital firm, has invested in Alignd, a Cape Town company that designs value-based care programmes for medical schemes. Coverage of the investment appeared on 12 November 2026. The money, from Knife Fund III, will support Alignd’s expansion beyond palliative care into maternity and kidney care.
The amount was not disclosed. TechMoran reports that “the companies did not disclose the size of the investment”, and WeeTracker describes the investment as undisclosed. We have not found a primary announcement from Alignd or Knife Capital. None of the coverage we reviewed gives an amount, a valuation or an instrument.
Paying for outcomes rather than activity
Alignd sells its programmes to medical schemes, not to patients. Instead of paying providers for each service, its model ties payment to patient outcomes, with the aim of aligning the interests of patients, providers and schemes. The trade press gives the company’s founding year as 2018.
The first programme covered palliative care. According to Africa Private Equity News, medical schemes have traditionally paid for costly in-hospital care at the end of life but not for home-based support. Alignd says it built a network of more than 500 providers delivering that care at home.
The results are the company’s own. Alignd reports a one-third reduction in non-beneficial chemotherapy in the final month of life, and says two-thirds of its patients died at home or in hospice. It also says schemes saved roughly R600 million, about $36 million. Africa Private Equity News says “more than” R600 million, while TechMoran says “approximately”. Alignd works with seven medical schemes, including GEMS, Fedhealth and Bonitas, and says its palliative programme covers more than 3.3 million lives. We did not find an independent evaluation of these figures.
Maternity and kidney care
Alignd’s maternity programme links parents, providers and schemes, with support tailored to each family. Its kidney care programme coordinates the clinical team for patients with chronic kidney disease, with the aim of preserving kidney function for as long as possible and helping schemes manage long-term costs.
TechMoran notes that these areas involve different treatment pathways, patient needs and financial incentives from palliative care. The coverage we reviewed does not report results from the new programmes yet.
Alignd’s chief executive, Dr Lungi Nyathi, said that “South Africa’s private healthcare system largely pays for activity rather than outcomes, and patients and their families often carry the cost of that misalignment”. Knife partner Catherine Young called Alignd “a women-founded team that has taken on a difficult problem in healthcare and proven that there is a better way to deliver care”.
Knife Capital presents the investment as part of its healthtech focus. Young said it “further strengthens the healthtech vertical we are building at Knife Capital”. For readers, the question is less the undisclosed amount than whether the palliative care results can be repeated in maternity and kidney care.
Sources
- Africa Private Equity News: Knife Capital invests in South African value-based care organisation Alignd (12 Nov 2026)
- TechMoran: Knife Capital Backs South African Healthtech Alignd After Its Healthcare Model Saves Insurers $36 Million (13 Nov 2026)
- WeeTracker: SA's Alignd Secures Knife Capital Investment To Expand Healthcare Programmes (12 Nov 2026)
